Available option
5mg
Lyophilised powder
- Strength
- 5mg
- Format
- Lyophilised powder
Bear Biotech catalogue
Ganirelix
GnRH receptor antagonist research material
- GnRH receptor antagonism
- LH/FSH dynamics
- Reproductive endocrinology
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is Ganirelix?
Ganirelix is a synthetic GnRH-receptor antagonist with established human reproductive-endocrine research. It is used to study rapid suppression of pituitary LH and FSH signalling and controlled gonadotropin dynamics. Published findings concern defined clinical formulations and do not establish equivalence for generic research material.
Human endocrine and reproductive clinical research exists; generic research material is not equivalent to an approved formulation.
Research focus
Key research areas
Ganirelix research: direct GnRH-receptor antagonism
Ganirelix is a synthetic antagonist of the gonadotropin-releasing-hormone receptor. Human studies measured pituitary gonadotropin signalling using defined formulations. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- GnRH receptor antagonism
- LH/FSH dynamics
- Reproductive endocrinology
Representative primary research
Representative research
Research focuses on competitive GnRH-receptor blockade, suppression of LH/FSH secretion and prevention of premature LH surges in controlled ovarian-stimulation studies.
- Ganirelix dose-finding prevention of premature LH surges ↗ Randomised human study of a defined clinical formulation; salt identity and catalogue equivalence are not established.
- Ganirelix prevents premature LH rises/luteinization ↗ Double-blind human trial of a defined clinical formulation; salt identity and catalogue equivalence are not established.
- Prospective trial of GnRH antagonists in a flexible assisted-reproduction protocol ↗ Randomised human study of defined clinical formulations; it does not establish the salt identity or equivalence of catalogue material.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- Ganirelix
- Research category
- GnRH receptor antagonist research material
- Evidence position
- Human endocrine and reproductive clinical research exists; generic research material is not equivalent to an approved formulation.
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
How does Ganirelix block GnRH-receptor signalling at the pituitary?
Ganirelix is studied as a GnRH-receptor antagonist at the pituitary. Blocking that receptor provides a controlled way to examine downstream LH and FSH signalling dynamics.
What do timed LH and FSH profiles show after Ganirelix exposure?
Timed LH and FSH measurements show the onset, magnitude and duration of pituitary gonadotropin suppression within a defined protocol. They do not establish an unrestricted product outcome.
Why must the Ganirelix salt form and formulation be documented?
Published Ganirelix evidence concerns specified salt forms and formulations. Generic research material is not equivalent to an approved formulation unless identity and composition are independently established.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.